XNYS
USNA
Market cap390mUSD
Jul 09, Last price
22.03USD
1D
4.06%
1Q
21.65%
Jan 2017
-64.00%
Name
USANA Health Sciences Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑00 | 2024‑12 | 2023‑12 | 2023‑12 | 2022‑12 | 2022‑00 | 2021‑12 | 2021‑00 | 2020‑12 | 2019‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||||||
Revenues | ||||||||||||||||
Cost of revenue | ||||||||||||||||
Unusual Expense (Income) | ||||||||||||||||
NOPBT | ||||||||||||||||
NOPBT Margin | ||||||||||||||||
Operating Taxes | ||||||||||||||||
Tax Rate | ||||||||||||||||
NOPAT | ||||||||||||||||
Net income | ||||||||||||||||
Dividends | ||||||||||||||||
Dividend yield | ||||||||||||||||
Proceeds from repurchase of equity | ||||||||||||||||
BB yield | ||||||||||||||||
| Debt | ||||||||||||||||
Debt current | ||||||||||||||||
Long-term debt | ||||||||||||||||
Deferred revenue | ||||||||||||||||
Other long-term liabilities | ||||||||||||||||
Net debt | ||||||||||||||||
| Cash flow | ||||||||||||||||
Cash from operating activities | ||||||||||||||||
CAPEX | ||||||||||||||||
Cash from investing activities | ||||||||||||||||
Cash from financing activities | ||||||||||||||||
FCF | ||||||||||||||||
| Balance | ||||||||||||||||
Cash | ||||||||||||||||
Long term investments | ||||||||||||||||
Excess cash | ||||||||||||||||
Stockholders' equity | ||||||||||||||||
Invested Capital | ||||||||||||||||
ROIC | ||||||||||||||||
ROCE | ||||||||||||||||
| EV | ||||||||||||||||
Common stock shares outstanding | ||||||||||||||||
Price | ||||||||||||||||
Market cap | ||||||||||||||||
EV | ||||||||||||||||
EBITDA | ||||||||||||||||
EV/EBITDA | ||||||||||||||||
Interest | ||||||||||||||||
Interest/NOPBT | ||||||||||||||||